Compare · AVTR vs NAUT
AVTR vs NAUT
Side-by-side comparison of Avantor Inc. (AVTR) and Nautilus Biotechnology Inc. (NAUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and NAUT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.56B, about 34.2x NAUT ($221.1M).
- AVTR has been more active in the news (3 items in the past 4 weeks vs 2 for NAUT).
- AVTR has more recent analyst coverage (25 ratings vs 7 for NAUT).
- Company
- Avantor Inc.
- Nautilus Biotechnology Inc.
- Price
- -
- -
- Market cap
- $7.56B
- $221.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 3
- 2
- Recent ratings
- 25
- 7
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest NAUT
- Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 4 filed by Director Posard Matthew L.
- SEC Form 4 filed by Director Akinsanya Karen
- SEC Form 4 filed by Director Nazem Farzad
- SEC Form 4 filed by Director Mcilwain Matthew S
- SEC Form 4 filed by Director Epperly Melissa B,
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Large owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)